• Foghorn Therapeutics Form 3 showed BVF group reporting as a 10% owner, event date Oct. 1, 2026.
• Group reported 8,346,168 common shares held directly across its funds.
• Also disclosed warrants for 9,512,297 shares, including 5,840,979 pre-funded warrants exercisable at $0.0001 per share.
• Series 1 warrants cover 1,835,659 shares at $13.42, expiring June 30, 2027.
• Series 2 warrants cover 1,835,659 shares at $20.13, expiring Dec. 31, 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foghorn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000921895-26-002730), on October 05, 2026, and is solely responsible for the information contained therein.